trending Market Intelligence /marketintelligence/en/news-insights/trending/YLgKhRLG8un8dPxAejhr9Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Roche's $4.3B takeover of Spark Therapeutics finally cleared in UK

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Roche's $4.3B takeover of Spark Therapeutics finally cleared in UK

Roche Holding AG's pending takeover of Spark Therapeutics Inc. has finally received approval in the U.K. after months of delays.

The U.K. Competition and Markets Authority granted unconditional clearance to Swiss drugmaker Roche's acquisition of Spark, a deal worth about $4.3 billion in cash.

In March, Roche launched a buyout offer to acquire all outstanding shares of the Philadelphia-based gene-therapy maker for $114.50 apiece. The offer has been extended several times to allow Britain's antitrust regulator and the U.S. Federal Trade Commission to look further into the deal.

After 10 extensions, the offer is set to expire at 5 p.m. ET on Dec. 16, unless further extended.

Deal closing is still subject to certain conditions, including expiration or termination of the waiting period under the Hart-Scott-Rodino Act, and the tender of the majority of Spark's shares.

MacKenzie Partners Inc. is information agent for the tender offer.